We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
2
1 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
N/A
Not yet recruiting
1
50.0%
Terminated
No approval data available
- Valerio Therapeutics signed a binding offer to acquire Etherna Immunotherapies for a total enterprise value of €30 million, combining complementary RNA platform technologies. - The merger pairs Valerio's single-domain antibody targeting and conjugation technologies with Etherna's mRNA and customizable lipid nanoparticle (cLNP) capabilities plus GMP manufacturing. - The combined entity aims to advance at least two immunological programs through IND-enabling studies and into the clinic within 18 to 24 months, led by an in vivo CAR-T approach targeting pathological B- and T-cells. - The transaction is supported by existing Valerio shareholders with secured financing and voting commitments representing over 70% of voting rights, with a six-week exclusivity period to finalize documentation.
